Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIS-101 intravitreal injection in treatment-naïve neovascular age-related macular degeneration
CTR20263188Phase 2Active
- Sponsor
- Ginkgo Bioworks
- Start
- Aug 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of ASKG712 in exudative macular degeneration, sponsored by Ginkgo Bioworks. Started Aug 2026; status: active.
02
Drugs
ASKG712
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on CTR20263188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263188.